During the corresponding time, Pulmonx Corporation saw a revenue deteriorated by -1.93 % year on year, sequentially revenue grew by 13.53 %. While revenue at the Pulmonx Corporation's corporate clients
Pulmonx's Comment on Sales, Marketing and Customers
The company serves physicians and hospitals that bill third-party payors, including commercial payors and government agencies, for patient treatment costs. Healthcare providers submit claims using standard codes such as CPT codes, which are published by the American Medical Association, to receive payments for physician and facility services. Medicare reimburses physicians based on a Physician Fee Schedule and hospitals through lump sum MS-DRG payments for inpatient procedures. Commercial payors use similar reimbursement methodologies with variable rates. Specific procedures referenced include the Zephyr Valve procedure and the use of the Chartis System for assessing collateral ventilation. Payment for these procedures generally covers associated costs, with no separate reimbursement provided for the Chartis System when used in conjunction with Zephyr Valves. The national Medicare average payment for physicians performing endobronchial valve procedures is consistent with payments for other complex bronchoscopic procedures.
Pulmonx’s Comment on Sales, Marketing and Customers
The company serves physicians and hospitals that bill third-party payors, including commercial payors and government agencies, for patient treatment costs. Healthcare providers submit claims using standard codes such as CPT codes, which are published by the American Medical Association, to receive payments for physician and facility services. Medicare reimburses physicians based on a Physician Fee Schedule and hospitals through lump sum MS-DRG payments for inpatient procedures. Commercial payors use similar reimbursement methodologies with variable rates. Specific procedures referenced include the Zephyr Valve procedure and the use of the Chartis System for assessing collateral ventilation. Payment for these procedures generally covers associated costs, with no separate reimbursement provided for the Chartis System when used in conjunction with Zephyr Valves. The national Medicare average payment for physicians performing endobronchial valve procedures is consistent with payments for other complex bronchoscopic procedures.
Sources:
Pulmonx Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Pulmonx Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Pulmonx Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
120.54 %